We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

51 hedge funds and large institutions have $162M invested in Dianthus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

6% more funds holding

Funds holding: 48 → 51 (+3)

0.13% more ownership

Funds ownership: 2.44% → 2.57% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less capital invested

Capital invested by funds: $182M → $162M (-$19.9M)

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
12
Reduced
5
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CC
Casdin Capital
New York
+$2.83M
2
OM
Opaleye Management
Massachusetts
+$2.3M
3
Fidelity International
Fidelity International
Bermuda
+$1.71M
4
BlackRock
BlackRock
New York
+$942K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$914K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.17M
3
Goldman Sachs
Goldman Sachs
New York
-$1.02M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$918K
5
Norges Bank
Norges Bank
Norway
-$893K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$40.1M – – –
CC
2
Casdin Capital
New York
$27M +$2.83M +13,437 +11%
EAM
3
Eventide Asset Management
Massachusetts
$26.3M – – –
EC
4
EcoR1 Capital
California
$18.5M – – –
Fidelity International
5
Fidelity International
Bermuda
$11.5M +$1.71M +8,144 +16%
OM
6
Opaleye Management
Massachusetts
$8.71M +$2.3M +10,938 +32%
Principal Financial Group
7
Principal Financial Group
Iowa
$4.94M +$16K +76 +0.3%
HMC
8
Harvard Management Company
Massachusetts
$4M – – –
LCM
9
Laurion Capital Management
New York
$3.41M -$866K -4,117 -19%
VOYA Investment Management
10
VOYA Investment Management
Georgia
$2.99M -$28.2K -134 -0.9%
AG
11
Artal Group
Luxembourg
$2.4M – – –
BlackRock
12
BlackRock
New York
$2.06M +$942K +4,477 +72%
ACP
13
Acuta Capital Partners
California
$2.04M – – –
NC
14
Nexthera Capital
New York
$1.8M – – –
Vanguard Group
15
Vanguard Group
Pennsylvania
$1.74M +$914K +4,341 +93%
SM
16
Sabby Management
Florida
$1.13M +$242K +1,151 +24%
PIM
17
Platinum Investment Management
Australia
$885K +$312K +1,481 +47%
Northern Trust
18
Northern Trust
Illinois
$655K +$543K +2,579 +311%
BG
19
Bollard Group
Massachusetts
$360K +$395K +1,875 New
NIP
20
Nicholas Investment Partners
California
$350K +$110K +525 +40%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$214K +$235K +1,116 New
Morgan Stanley
22
Morgan Stanley
New York
$195K +$207K +983 +3,171%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$182K +$200K +951 New
TAM
24
Tiverton Asset Management
Delaware
$111K – – –
Deutsche Bank
25
Deutsche Bank
Germany
$110K -$143K -679 -54%
1
2 3

DNTH Hedge Fund Activity: Q3 2018 in Review

51 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2018, worth a combined $162M — down 11% from $182M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new DNTH positions and 16 closed out — a net gain of 3 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Casdin Capital, adding an estimated $2.83M. The largest seller was Millennium Management, exiting entirely with an estimated $1.51M sold.

  • 51 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2018, up from 48 in Q2 2018.
  • Funds reported $162M of Dianthus Therapeutics stock for Q3 2018, down 11% quarter-over-quarter.
  • 19 funds opened new Dianthus Therapeutics positions in Q3 2018 and 16 closed out, a net change of +3 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2018 was Casdin Capital, an estimated $2.83M added.
  • The largest Dianthus Therapeutics seller in Q3 2018 was Millennium Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q3 2018.